-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OQkdie/Xjb/Mc3BK0qyOKG+OMfGd4lqhSZnJGkGTiC/Sux4J7uEOD9r5tntD8eL9 Sxgm6U0v2f4EVEHgiJnReg== 0000914062-05-000460.txt : 20050707 0000914062-05-000460.hdr.sgml : 20050707 20050707170328 ACCESSION NUMBER: 0000914062-05-000460 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20050701 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20050707 DATE AS OF CHANGE: 20050707 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CRYOLIFE INC CENTRAL INDEX KEY: 0000784199 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 592417093 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13165 FILM NUMBER: 05943970 BUSINESS ADDRESS: STREET 1: 1655 ROBERTS BOULEVARD N W STREET 2: STE 142 CITY: KENNESAW STATE: GA ZIP: 30144 BUSINESS PHONE: 7704193355 MAIL ADDRESS: STREET 1: 1655 ROBERTS BOULEVARD N W STREET 2: STE 142 CITY: KENNESAW STATE: GA ZIP: 30144 8-K 1 cryolife8k70105.txt FORM 8-K - -------------------------------------------------------------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 -------------------------------- FORM 8-K -------------------------------- CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): JULY 1, 2005 ----------------------- CRYOLIFE, INC. (Exact name of registrant as specified in its charter) -------------------------
FLORIDA 1-13165 59-2417093 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1655 ROBERTS BOULEVARD N.W., KENNESAW, GA 30144 (Address of principal executive office) (zip code) Registrant's telephone number, including area code: (770) 419-3355 N/A (Former name or former address, if changed since last report) ------------------------- Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) - -------------------------------------------------------------------------------- SECTION 1 REGISTRANT'S BUSINESS AND OPERATIONS ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. Gerald B. Seery has been appointed to the newly created position of Vice President of International Operations of CryoLife, Inc. ("CryoLife"), effective July 1, 2005. Mr. Seery had been President of CryoLife Europa, based in the U.K. for the past three years. Effective July 1, 2005, Mr. Seery receives a base salary of $250,000, plus a percentage of net increases in CryoLife's non-United States' revenues. Mr. Seery is not currently employed pursuant to an written employment agreement, however, his employment is subject to a 30 day notice of termination requirement. SECTION 8 OTHER EVENTS ITEM 8.01 OTHER EVENTS. On July 7, 2005, CryoLife announced in a press release that it had appointed Gerald B. Seery to the newly created position of Vice President of International Operations. SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS ITEM 9.01 EXHIBITS. (a) Financial Statements (b) Pro Forma Financial Information (c) Exhibits Exhibit Number Description -------------- ----------- 99.1 Press Release dated July 7, 2005 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CRYOLIFE, INC. Date: July 7, 2005 By: /s/ D.A. Lee ---------------------------------------- D. Ashley Lee, Executive Vice President, Chief Operating Officer and Chief Financial Officer 3 EXHIBIT INDEX Exhibit Number Description -------------- ----------- 99.1 Press Release dated July 7, 2005 4 EX-99.1 2 cryolife8k70105ex99.txt PRESS RELEASE EXHIBIT 99.1 [COMPANY LOGO] FOR IMMEDIATE RELEASE CONTACT: JOSEPH T. SCHEPERS VICE PRESIDENT, CORPORATE COMMUNICATIONS (770) 419-3355 CRYOLIFE APPOINTS GERALD B. SEERY VICE PRESIDENT OF INTERNATIONAL OPERATIONS ATLANTA, GEORGIA... (JULY 7, 2005)... CRYOLIFE, INC. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that Gerald B. Seery has been appointed to the newly created position of Vice President of International Operations. Mr. Seery has been President of CryoLife Europa, based in the U.K. for the past three years, and has returned to the corporate headquarters in Kennesaw, Georgia. Mr. Seery joined CryoLife in 1993 and has held several positions with the Company including Marketing Manager for vascular tissues, Director of Marketing, Vice President of Marketing, and President of the Aurazyme subsidiary. He is a graduate of The Catholic University of America and has an MBA from Columbia University. Mr. Seery will continue to report to Steven G. Anderson, President and CEO of CryoLife, Inc. Steven G. Anderson, President and CEO of CryoLife, Inc. stated, "One of the key areas of opportunity and growth for the Company is our international business. CryoLife's international BioGlue(R) sales increased 27% in the first quarter of 2005 compared to the first quarter of 2004. Approximately 22% of BioGlue sales are derived outside the U.S. The consolidation of all of the Company's international operations under Gerry Seery's leadership will enable us to increase our efforts to develop and introduce products in geographic regions outside of the U.S." The Company markets the Model #100 SynerGraft AV access device, the O'Brien stentless porcine heart valve and BioGlue surgical adhesive in international markets at this time. The Company markets and distributes its products in approximately 60 countries throughout the world. The Company also recently announced its research collaboration with The Magdi Yacoub Institute at The Imperial College in London, U.K. to improve xenografts for human transplantation. ABOUT CRYOLIFE Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular and vascular surgeries throughout the United States and Canada. The Company's BioGlue Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada for use in soft tissue repair and approved in Australia for use in vascular and pulmonary sealing and repair. For additional information about the company, visit CryoLife's web site: http://www.cryolife.com END -----END PRIVACY-ENHANCED MESSAGE-----